Role of incretin based therapies in the treatment of diabetic kidney disease

Diabetic kidney disease (DKD), a serious microvascular complication of diabetes mellitus is a leading cause of end-stage renal disease and is associated with an increased risk of cardiovascular morbidity and mortality. Despite advancements in blood glucose and blood pressure (BP) control, ~20% to 40...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Paola Fioretto, Andrea Frascati
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2018
Materias:	type 2 diabetes mellitus diabetic kidney disease diabetic nephropathy incretins dpp-4 inhibitors glp-1 receptor agonists Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/e96ccbff02ea4c3eb6e487f109d992fc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e96ccbff02ea4c3eb6e487f109d992fc
record_format	dspace
spelling	oai:doaj.org-article:e96ccbff02ea4c3eb6e487f109d992fc2021-11-14T09:00:22ZRole of incretin based therapies in the treatment of diabetic kidney disease2072-03512072-037810.14341/DM9845https://doaj.org/article/e96ccbff02ea4c3eb6e487f109d992fc2018-11-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/9845https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Diabetic kidney disease (DKD), a serious microvascular complication of diabetes mellitus is a leading cause of end-stage renal disease and is associated with an increased risk of cardiovascular morbidity and mortality. Despite advancements in blood glucose and blood pressure (BP) control, ~20% to 40% of patients with diabetes mellitus develop DKD. Intensive glycaemic and BP control positively influence decline in estimated glomerular filtration rate and albuminuria, thereby delaying the onset and progression of diabetic nephropathy. Incretin based therapies namely glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used glucose lowering agents and have shown favorable renal outcomes in DKD. This article discusses the extra-glycaemic properties of incretin based therapies and their renoprotective effects on components of the metabolic syndrome, including obesity, hypertension and dyslipidaemia; reduction in oxidative stress and inflammation; and increase in natriuresis.Paola FiorettoAndrea FrascatiEndocrinology Research Centrearticletype 2 diabetes mellitusdiabetic kidney diseasediabetic nephropathyincretinsdpp-4 inhibitorsglp-1 receptor agonistsNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 21, Iss 5, Pp 395-398 (2018)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes mellitus diabetic kidney disease diabetic nephropathy incretins dpp-4 inhibitors glp-1 receptor agonists Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes mellitus diabetic kidney disease diabetic nephropathy incretins dpp-4 inhibitors glp-1 receptor agonists Nutritional diseases. Deficiency diseases RC620-627 Paola Fioretto Andrea Frascati Role of incretin based therapies in the treatment of diabetic kidney disease
description	Diabetic kidney disease (DKD), a serious microvascular complication of diabetes mellitus is a leading cause of end-stage renal disease and is associated with an increased risk of cardiovascular morbidity and mortality. Despite advancements in blood glucose and blood pressure (BP) control, ~20% to 40% of patients with diabetes mellitus develop DKD. Intensive glycaemic and BP control positively influence decline in estimated glomerular filtration rate and albuminuria, thereby delaying the onset and progression of diabetic nephropathy. Incretin based therapies namely glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used glucose lowering agents and have shown favorable renal outcomes in DKD. This article discusses the extra-glycaemic properties of incretin based therapies and their renoprotective effects on components of the metabolic syndrome, including obesity, hypertension and dyslipidaemia; reduction in oxidative stress and inflammation; and increase in natriuresis.
format	article
author	Paola Fioretto Andrea Frascati
author_facet	Paola Fioretto Andrea Frascati
author_sort	Paola Fioretto
title	Role of incretin based therapies in the treatment of diabetic kidney disease
title_short	Role of incretin based therapies in the treatment of diabetic kidney disease
title_full	Role of incretin based therapies in the treatment of diabetic kidney disease
title_fullStr	Role of incretin based therapies in the treatment of diabetic kidney disease
title_full_unstemmed	Role of incretin based therapies in the treatment of diabetic kidney disease
title_sort	role of incretin based therapies in the treatment of diabetic kidney disease
publisher	Endocrinology Research Centre
publishDate	2018
url	https://doaj.org/article/e96ccbff02ea4c3eb6e487f109d992fc
work_keys_str_mv	AT paolafioretto roleofincretinbasedtherapiesinthetreatmentofdiabetickidneydisease AT andreafrascati roleofincretinbasedtherapiesinthetreatmentofdiabetickidneydisease
_version_	1718429498668482560

Role of incretin based therapies in the treatment of diabetic kidney disease

Ejemplares similares